Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study IV QUZYTTIRâ„¢ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2019
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2019
Lead Product(s) : Cetirizine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cetirizine Chewable Bioequivalence and Food Effect Study
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2018
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2016
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2016
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Biogenics Research Chamber, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparability and Standardization of Controlled Allergen Challenge Facilities
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2015
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Biogenics Research Chamber, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2014
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : McNeil Consumer Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Bronchodilation Effects of Cetirizine
Details : Cetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : McNeil Consumer Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Details : AC-170 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2012
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
